v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenues:    
Royalties $ 5,826 $ 3,060
Material sales 1,539 667
Collaborative research and development and other revenues 4,286 1,909
Total revenues 11,651 5,636
Operating costs and expenses:    
Cost of sales 663 155
Research and development 2,465 2,817
General and administrative 4,502 3,416
Lease exit and termination costs 89 87
Total operating costs and expenses 7,719 6,475
Income (loss) from operations 3,932 (839)
Other income (expense):    
Interest expense, net (912) (701)
(Increase) decrease in contingent liabilities (1,841) 513
Other, net 191 254
Total other (expense) income, net (2,562) 66
Income (loss) before income taxes 1,370 (773)
Income tax (expense) benefit (66) 35
Income (loss) from continuing operations 1,304 (738)
Discontinued operations:    
Gain on sale of Avinza Product Line before income taxes 191 2,048
Income tax expense on discontinued operations    (177)
Income from discontinued operations 191 1,871
Net income: $ 1,495 $ 1,133
Basic and diluted per share amounts:    
Income (loss) from continuing operations (in usd per share) $ 0.06 $ (0.04)
Discontinued operations (in usd per share) $ 0.01 $ 0.10
Net income (loss) (in usd per share) $ 0.07 $ 0.06
Weighted average number of common shares-basic (in shares) 20,189,378 19,709,078
Weighted average number of common shares-diluted (in shares) 20,280,030 19,738,801